A Phase 2 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed or Refractory CD10-Negative Diffuse-Large B-Cell Lymphoma (DLBCL) and High-Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements (HGBCL-DH-BCL2)

This phase II trial tests how well venetoclax, ibrutinib, prednisone, obinutuzumab, and Revlimid® (ViPOR) works in treating patients with CD10 negative diffuse large B-cell lymphoma (DLBCL) and high-grade lymphoma with MYC and BCL2 rearrangements that has come back after a period of improvement (relapsed) and/or that has not responded to previous treatment (refractory). Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Ibrutinib is in a class of medications called kinase inhibitors. It blocks a protein called BTK, which is present on B-cell (a type of white blood cells) cancers at abnormal levels. This may help keep cancer cells from growing and spreading. Anti-inflammatory drugs, such as prednisone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Obinutuzumab, a monoclonal antibody, binds to a protein called CD20, which is found on B cells and some types of leukemia and lymphoma cells. Obinutuzumab may block CD20 and help the immune system kill cancer cells. Revlimid, a type of anti-angiogenesis agent and a type of immunomodulating agent, may help the immune system kill abnormal blood cells or cancer cells. It may also prevent the growth of new blood vessels that cancers need to grow. ViPOR may be an effective treatment option for patients with relapsed and/or refractory CD10 negative DLBCL and high-grade B-cell lymphoma with MYC and BCL2 rearrangements.

开始日期2025-01-17

申办/合作机构

National Cancer Institute

IRCT20210519051345N71

/ SuspendedN/AIIT

In vivo fasted-state bioequivalence study of Ibrutinib 140 mg Capsules manufactured by Sobhan oncology Pharmaceutical Co. compared to innovator product

开始日期2025-01-09

申办/合作机构

Tabriz University of Medical Sciences

NCT06271616

/ Recruiting临床2期IIT

A Phase II Study of Ibrutinib As Prophylaxis for Chronic Graft-Versus-Host Disease (GVHD) in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation (allo-HCT)

This phase II trial tests how well ibrutinib works in preventing chronic graft-versus-host disease (GVHD) in patients undergoing donor (allogeneic) hematopoietic cell transplantation (HCT). An allogeneic hematopoietic cell transplantation (allo-HCT) is a treatment in which a person receives blood-forming stem cells (cells from which all blood cells develop) from a genetically similar, but not identical donor. When healthy stem cells from a donor are infused into a patient, they may help the patient's bone marrow make more healthy cells and platelets. However, sometimes the transplanted cells from a donor can attack the body's normal cells (called GVHD). Giving ibrutinib after the transplant may stop that from happening. Ibrutinib is in a class of medications called kinase inhibitors. It works by blocking a protein in the blood called Bruton's tyrosine kinase (BTK). By blocking BTK, ibrutinib inhibits certain immune cells that play a role in cGVHD. Giving ibrutinib after an allo-HCT may prevent the development of chronic GVHD.

开始日期2024-12-13

申办/合作机构

Mayo Clinic

100 项与伊布替尼相关的临床结果

登录后查看更多信息

100 项与伊布替尼相关的转化医学

登录后查看更多信息

100 项与伊布替尼相关的专利（医药）

登录后查看更多信息

3,988

项与伊布替尼相关的文献（医药）

2025-12-01·Blood Research

Relative efficacy of systemic treatments for patients with relapsed/refractory chronic lymphocytic leukemia: a network meta-analysis according to 17p deletion/TP53 mutations

Article

作者: Lee, Moon Hee ; Lim, Joo Han ; Cho, Jinhyun ; Kim, Jinchul

AbstractPurposeThis network meta-analysis aimed to evaluate the relative efficacy of systemic treatments in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL), focusing on key genetic mutations, specifically the 17p deletion and TP53 mutations.MethodsWe conducted a systematic literature review to identify all publicly available randomized controlled trials (RCTs) using PubMed, EMBASE, the Cochrane database, and meeting abstracts published through December 2023. A Bayesian network meta-analysis was performed to estimate the hazard ratios (HRs) for progression-free survival (PFS) with 95% confidence intervals (CIs) and to determine the ranking of the included regimens.ResultsTwelve trials involving 4,437 patients and 13 treatment options were included in the meta-analysis. Venetoclax plus rituximab and zanubrutinib emerged as the most effective treatments for the overall R/R CLL population, showing the lowest PFS HR (HR 0.62, 95% CI 0.32–1.20 and HR 0.65, 95% CI 0.49–0.86, respectively) versus ibrutinib, and were ranked as the best agent (surface under the cumulative ranking curve [SUCRA] value of both 90%, respectively) among the included drugs. In the 17p deletion/TP53 mutation subgroup, zanubrutinib demonstrated the most favorable efficacy (HR 0.52, 95% CI 0.31–0.88 versus ibrutinib) with the highest SUCRA value (97%). In patients without these mutations, venetoclax plus rituximab was the most effective (HR 0.49, 95% CI 0.26–0.94 versus ibrutinib) with a SUCRA value of 94%.ConclusionOur findings highlight the superior efficacy of venetoclax plus rituximab and zanubrutinib for treating R/R CLL and confirm that the role of each regimen may vary depending on the clinically significant mutations.

2025-03-01·Journal of Pharmaceutical and Biomedical Analysis

Differentiation of the chronic lymphocytic leukemia response to ibrutinib and acalabrutinib treatment by single-cell MALDI-TOF MS imaging

Article

作者: Kotris, Ana ; Lukić, Iva ; Pavičić, Ema ; Lukić, Maja ; Dmitrović, Branko ; Mrđenović, Stefan ; Debeljak, Željko ; Marković, Ivana

Ibrutinib and acalabrutinib, Bruton's tyrosine kinase inhibitors (BTKi) used for chronic lymphocytic leukemia (CLL) treatment, aim the same target but their off-target effects are different. The aim of this study was to use single-cell MALDI TOF mass spectrometry imaging to compare the CD19+ lymphocytes' mass spectra in untreated and ibrutinib- or acalabrutinib-treated subjects in order to better understand the therapeutic effect of BTKi. 180 cells from 9 male subjects divided in 3 groups (untreated, ibrutinib-treated and acalabrutinib-treated) were analyzed using MALDI-TOF mass spectrometry analyzer. Mass spectra were acquired in the 300-600 Da mass range. Partial least squares discriminant analysis (PLS-DA) was used for evaluation of mass spectra, while Volcano plots and Venn diagram were used for a review of significantly altered m/z values. Cross-validated PLS-DA classification accuracy of cells was 85 %. Ibrutinib-treated cells overlap with the untreated cell population, while acalabrutinib-treated cells form a separate class. 13 m/z signals were specific for each BTKi group. In conclusion, single-cell MALDI-TOF mass spectrometry imaging detects differences in the mass spectra of CD19+ lymphocytes treated with two different BTKi. Drug-specific m/z signal clusters can be identified as a chemical fingerprint of the BTKi effect and represent candidates for the therapeutic response biomarkers.

2025-02-01·Critical Reviews in Oncology/Hematology

Efficacy and safety of ibrutinib in central nervous system lymphoma: A systematic review and meta-analysis

Review

作者: Nashwan, Abdulqadir J ; Al-Bojoq, Yousef ; Alkhawaldeh, Ibraheem M ; Jaradat, Jaber H ; Ramadan, Monther N ; Abuawwad, Mohammad T ; Alabdallat, Yasmeen Jamal

BACKGROUNDPrimary central nervous system lymphoma (CNSL) is a rare, aggressive non-Hodgkin lymphoma confined to the CNS. Although radiation and chemotherapy, particularly high-dose methotrexate (HD-MTX), are effective treatments, the relapse rates remain high, prompting the exploration of novel therapeutic options. Ibrutinib, an irreversible Bruton tyrosine kinase (BTK) inhibitor, has shown promise in various B-cell malignancies, including CNSL.OBJECTIVESThis systematic review and meta-analysis aimed to evaluate the safety and efficacy of ibrutinib in the treatment of CNSL, focusing on overall response (OR), complete response (CR), partial response (PR), progression-free survival (PFS), overall survival (OS), and adverse events.METHODSA comprehensive search of the PubMed, Google Scholar, and Scopus databases was conducted. The included studies were prospective and retrospective studies focusing on ibrutinib as monotherapy or in combination with CNSL. Data extraction and quality assessment were independently performed by two reviewers, and statistical analyses were conducted using R version 4.4.0.RESULTSFourteen studies (eight cohort studies and six clinical trials) involving 784 patients were included. The median age was 61 years, with nearly equal sex distribution. The meta-analysis for CNSL, the partial response rate was 29.52 %, complete response rate was 49.19 %, and overall response rate was 72.11 %. For PCNSL, the partial response rate was 20.85 %, complete response rate was 48.13 %, and overall response rate was 66.92 %. For SCNSL, the partial response rate was 29.42 %, complete response rate was 44.64 %, and overall response rate was 66.82 %. Significant heterogeneity was observed in some comparisons. There were no significant differences in the efficacy of ibrutinib between CNSL subtypes.CONCLUSIONSIbrutinib shows promising efficacy in improving partial and complete response rates in CNSL. The substantial heterogeneity observed underscores the need for further well-designed studies to confirm these findings and explore the optimal use of ibrutinib in CNSL treatment protocols. Future trials should consider comparing ibrutinib to standard therapies and investigate its long-term efficacy and safety profile.

1,432

项与伊布替尼相关的新闻（医药）

2025-01-20

·Pharmaceutical Technology

AstraZeneca secures first BTK approval in first-line mantle cell lymphoma

Calquence is forecast to generate up to $4.7bn in sales by 2030, as per GlobalData intelligence. Credit: Nadezhda Fedrunova via Getty Images. AstraZeneca has received approval from the US Food and Drug Administration (FDA) for its Bruton’s tyrosine kinase (BTK) inhibitor, Calquence (acalabrutinib), for first-line use in mantle cell lymphoma (MCL). This approval makes Calquence the first BTK inhibitor available for adults with untreated MCL who are unsuitable for autologous haematopoietic stem cell transplantation (HSCT) and allows its use in combination with chemoimmunotherapy. The FDA granted approval based on data from the Phase III ECHO trial (NCT02972840). The randomised, double-blind, placebo-controlled study enrolled 598 patients aged 65 or older with untreated MCL who were unsuitable for HSCT. Patients were randomised to receive Calquence with chemotherapy bendamustine and Biogen and Genentech’s Rituxan (rituximab) or placebo plus bendamustine and Rituxan. Efficacy was measured by progression-free survival (PFS) and evaluated by an independent review committee. The median PFS was 66.4 months in the Calquence plus BR arm, compared to 49.6 months in the placebo plus bendamustine and Rituxan arm. The trial demonstrated a 27% improvement in PFS for Calquence over placebo. MCL is a rare and aggressive subtype of non-Hodgkin lymphoma, often diagnosed in later stages and characterised by the malignant transformation of B lymphocytes in the lymph node mantle zone. Calquence, a next-generation selective and irreversible BTK inhibitor, binds covalently to the BTK active site to inhibit enzymatic activity, suppressing the proliferation and survival of malignant B cells. AstraZeneca’s Calquence now holds a first-mover advantage in the treatment-naive MCL market, outpacing competitors such as BeiGene’s Brukinsa (zanubrutinib), Eli Lilly’s Jaypirca (pirtobrutinib), InnoCare’s Inokai (orelabrutinib), all of which remain in late-stage clinical trials for this indication. AbbVie and Johnson & Johnson’s (J&J’s) Imbruvica (ibrutinib) was previously positioned to lead the market but lost its accelerated approval in 2023 after the Phase III SHINE trial (NCT01776840) showed no overall survival benefit and a 7% increase in mortality risk for Imbruvica-treated patients. GlobalData projects that Calquence could generate up to $4.7bn in sales by 2030. With this FDA approval, AstraZeneca is poised to capitalise on its lead in the competitive BTK inhibitor market. GlobalData is the parent company of Pharmaceutical Technology.

临床3期上市批准临床结果免疫疗法加速审批

2025-01-19

·药筛

两性霉素B脂质体国产第4家，河南中帅右哌甲酯缓释胶囊首家上市 | 仿制药周报（1.12-1.19）

统计每周仿制药一致性评价申报、上市申请（1.12-1.19） 1、仿制药上市申请获批药品名称企业名称分类受理号氨氯地平贝那普利胶囊河北龙海药业有限公司3CYHS2301852氨溴特罗口服溶液南京创迪生物技术有限公司;江苏贝佳制药有限公司3CYHS2302950奥拉帕利片Natco Pharma Limited5.2JYHS2300075奥拉帕利片Natco Pharma Limited5.2JYHS2300074奥美拉唑碳酸氢钠干混悬剂湖北邦泽医药有限公司;哈尔滨美君制药有限公司3CYHS2301623奥美沙坦酯氨氯地平片裕松源药业有限公司4CYHS2404050贝前列素钠片江西科睿药业有限公司4CYHS2303507苯磺酸氨氯地平片广州一品红制药有限公司4CYHS2303192苯磺酸氨氯地平片广州一品红制药有限公司4CYHS2303193吡拉西坦注射液西安达莫制药有限公司;山东华鲁制药有限公司3CYHS2400403玻璃酸钠滴眼液辅必成（上海）医药科技有限公司;浙江赛默制药有限公司4CYHS2400844达比加群酯胶囊浙江诺得药业有限公司4CYHS2303164达比加群酯胶囊浙江诺得药业有限公司4CYHS2303162达比加群酯胶囊浙江诺得药业有限公司4CYHS2303163地夸磷索钠滴眼液山东诺明康药物研究院有限公司;山东光明药业有限公司4CYHS2302729地诺孕素片南通联亚药业股份有限公司4CYHS2301847二羟丙茶碱注射液河北千康医药科技有限责任公司;青岛金峰制药有限公司3CYHS2302021非那雄胺片乐泰药业有限公司;南京海纳制药有限公司4CYHS2302057非那雄胺片乐泰药业有限公司;南京海纳制药有限公司4CYHS2302056复方氨基酸注射液(18AA-Ⅸ)四川科伦药业股份有限公司4CYHS2302546复方甘草酸苷片东阳祥昇医药科技有限公司;浙江北生药业汉生制药有限公司4CYHS2301720富马酸福莫特罗吸入溶液南京力成药业有限公司4CYHS2303034富马酸福莫特罗吸入溶液长风药业股份有限公司4CYHS2302621腹膜透析液(艾考糊精)芜湖道润药业有限责任公司4CYHS2401530钆喷酸葡胺注射液四川国瑞药业有限责任公司4CYHS2301898甲苯磺酸艾多沙班片齐鲁制药有限公司4CYHS2302691甲苯磺酸艾多沙班片齐鲁制药有限公司4CYHS2302693甲苯磺酸艾多沙班片齐鲁制药有限公司4CYHS2302692甲钴胺注射液广州一品红制药有限公司;河北凯威制药有限责任公司4CYHS2303000甲磺酸仑伐替尼胶囊吉林敖东洮南药业股份有限公司4CYHS2301718甲磺酸仑伐替尼胶囊吉林敖东洮南药业股份有限公司4CYHS2301719间苯三酚注射液江苏悦兴药业有限公司4CYHS2302047酒石酸溴莫尼定滴眼液广东众生药业股份有限公司4CYHS2303512磷酸奥司他韦胶囊福建省闽东力捷迅药业股份有限公司4CYHS2400923磷酸奥司他韦胶囊植恩生物技术股份有限公司4CYHS2400901硫酸羟氯喹片福建广生堂药业股份有限公司4CYHS2303516硫酸特布他林雾化吸入用溶液浙江金华康恩贝生物制药有限公司4CYHS2301885氯雷他定糖浆南通广承制药有限公司;江苏广承药业有限公司4CYHS2302830氯沙坦钾氢氯噻嗪片裕松源药业有限公司4CYHS2404128罗沙司他胶囊北京福元医药股份有限公司4CYHS2302941罗沙司他胶囊北京福元医药股份有限公司4CYHS2302942罗沙司他胶囊广州康臣药业有限公司;成都倍特药业股份有限公司4CYHS2302564罗沙司他胶囊哈尔滨三联药业股份有限公司;兰西哈三联制药有限公司4CYHS2302026罗沙司他胶囊哈尔滨三联药业股份有限公司;兰西哈三联制药有限公司4CYHS2302025马来酸阿伐曲泊帕片湖南明瑞制药股份有限公司4CYHS2302991马来酸阿伐曲泊帕片瑞阳制药股份有限公司4CYHS2302556马来酸咪达唑仑片宜昌人福药业有限责任公司4CYHS2302782玛巴洛沙韦片郑州泰丰制药有限公司4CYHS2302877尼可地尔片浙江赛默制药有限公司4CYHS2303503帕拉米韦注射液长春澜江医药科技有限公司;山东新时代药业有限公司3CYHS2302932普瑞巴林口服溶液常州四药制药有限公司3CYHS2301334乳果糖口服溶液安徽美来药业股份有限公司;安徽永生堂药业有限责任公司4CYHS2302196沙库巴曲缬沙坦钠片江苏德源药业股份有限公司4CYHS2303296羧甲司坦口服溶液海南斯达制药有限公司3CYHS2300946托吡酯片海南日中天制药有限公司4CYHS2301074吸入用布地奈德混悬液浙江高跖医药科技股份有限公司;浙江赛默制药有限公司4CYHS2302457西格列汀二甲双胍片(Ⅱ)江苏康缘药业股份有限公司4CYHS2302127盐酸氮卓斯汀滴眼液浙江视方极医药科技有限公司;浙江赛默制药有限公司4CYHS2303213盐酸氮卓斯汀滴眼液浙江视方极医药科技有限公司;浙江赛默制药有限公司4CYHS2302677盐酸莫西沙星片河北天成药业股份有限公司4CYHS2302521盐酸伊托必利片裕松源药业有限公司4CYHS2404103盐酸右哌甲酯缓释胶囊河南中帅药业有限公司3CYHS2303628伊布替尼胶囊江西科睿药业有限公司4CYHS2302871异丙托溴铵雾化吸入溶液浙江金华康恩贝生物制药有限公司4CYHS2302237注射用两性霉素B脂质体江西艾施特制药有限公司4CYHS2301518注射用替考拉宁重庆药友制药有限责任公司4CYHS2301539注射用紫杉醇(白蛋白结合型)河北天成药业股份有限公司;河北道恩药业有限公司4CYHS2303294 注：灰色字体部分受理号结论为不批准。 2、一致性评补充申请获批药品名称企业名称受理号硫酸阿托品注射液湖北美林药业有限公司;天津金耀药业有限公司CYHB2350793马来酸曲美布汀片信合援生制药股份有限公司CYHB2350919碳酸氢钠注射液河北天成药业股份有限公司CYHB2350816碳酸氢钠注射液河北天成药业股份有限公司CYHB2350815碳酸氢钠注射液湖南科伦制药有限公司CYHB2350800碳酸氢钠注射液湖南科伦制药有限公司CYHB2350799依达拉奉注射液北京四环制药有限公司;吉林四环制药有限公司CYHB2350087依达拉奉注射液华润双鹤药业股份有限公司CYHB2250464吲达帕胺片上海迪冉郸城制药有限公司CYHB2450115注射用奥美拉唑钠常州四药制药有限公司CYHB2350953注射用头孢唑肟钠汕头金石粉针剂有限公司CYHB2350958注射用维库溴铵海南斯达制药有限公司CYHB2350684 注：灰色字体部分受理号结论为不批准。 3、新增仿制药上市申请药品名称企业名称分类受理号阿司匹林肠溶片华中药业股份有限公司4CYHS2500315阿昔莫司胶囊天津掌心医药科技有限公司;淄博万杰制药有限公司4CYHS2500359艾拉莫德片宁夏康亚药业股份有限公司4CYHS2500290艾普拉唑肠溶片北京福元医药股份有限公司4CYHS2500267氨酚羟考酮片河北奥星集团药业有限公司3CYHS2500297氨溴特罗口服溶液江苏神华药业有限公司;安徽永生堂药业有限责任公司3CYHS2500307苯溴马隆片沐源（安徽）药业有限公司;华益药业科技（安徽）有限公司3CYHS2500325苯溴马隆片广州一品红制药有限公司3CYHS2500326比拉斯汀片江苏联环药业股份有限公司4CYHS2500324比索洛尔氨氯地平片海南广升誉制药有限公司;华益泰康药业股份有限公司4CYHS2500343吡拉西坦注射液石药银湖制药有限公司3CYHS2500336别嘌醇片安徽圣鹰药业有限公司3CYHS2500282玻璃酸钠滴眼液修正药业集团长春高新制药有限公司4CYHS2500306布美他尼注射液浙江赛默制药有限公司3CYHS2500331布美他尼注射液浙江赛默制药有限公司3CYHS2500330布瑞哌唑片浙江华义制药有限公司4CYHS2500280布瑞哌唑片浙江华义制药有限公司4CYHS2500281草酸艾司西酞普兰片山东普瑞曼药业有限公司4CYHS2500272蛋白琥珀酸铁口服溶液国药控股星鲨制药（厦门）有限公司4CYHS2500266地屈孕酮片M/s MANKIND PHARMA LIMITED5.2JYHS2500004碘佛醇注射液山东齐都药业有限公司;博瑞制药（苏州）有限公司4CYHS2500275二十碳五烯酸乙酯软胶囊北京诚济制药股份有限公司;人福普克药业（武汉）有限公司4CYHS2500358二十碳五烯酸乙酯软胶囊浙江创新生物有限公司4CYHS2500312氟脲嘧啶注射液海南倍特药业有限公司3CYHS2500316氟脲嘧啶注射液海南倍特药业有限公司3CYHS2500317复方氨基酸(15)双肽(2)注射液成都诺和晟鸿生物制药有限公司;四川美大康佳乐药业有限公司4CYHS2500268复方氨基酸(15)双肽(2)注射液成都诺和晟鸿生物制药有限公司;四川美大康佳乐药业有限公司4CYHS2500269富马酸伏诺拉生片浙江华海药业股份有限公司4CYHS2500278富马酸伏诺拉生片浙江华海药业股份有限公司4CYHS2500277富马酸酮替芬滴眼液石家庄格瑞药业有限公司3CYHS2500328富马酸酮替芬滴眼液石家庄格瑞药业有限公司3CYHS2500329富马酸依美斯汀滴眼液广州大光制药有限公司4CYHS2500349枸橼酸西地那非口崩片东莞松山湖美健生物技术有限公司;东莞市金美济药业有限公司4CYHS2500293枸橼酸西地那非口崩片南京康川济医药科技有限公司;浙江四维医药科技有限公司4CYHS2500283己酮可可碱缓释片浙江普洛康裕制药有限公司3CYHS2500327己酮可可碱缓释片福建海西新药创制股份有限公司;广东安诺药业股份有限公司3CYHS2500310甲硝唑阴道凝胶杭州上禾健康科技有限公司;浙江鼎泰药业股份有限公司3CYHS2500352精氨酸布洛芬片海南赛立克药业有限公司4CYHS2500294酒石酸阿福特罗雾化吸入溶液江苏长泰药业股份有限公司3CYHS2500279聚多卡醇注射液海南合瑞制药股份有限公司4CYHS2500318聚多卡醇注射液海南合瑞制药股份有限公司4CYHS2500319聚乙二醇钠钾散湖北唯森制药有限公司4CYHS2500334聚乙二醇钠钾散郑州泰丰制药有限公司4CYHS2500338聚乙烯醇滴眼液南京恒道医药科技股份有限公司;江苏大红鹰恒顺药业有限公司4CYHS2500321糠酸莫米松乳膏江苏知原药业股份有限公司4CYHS2500288利丙双卡因乳膏江苏吴中医药集团有限公司苏州制药厂;浙江赛默制药有限公司4CYHS2500322硫酸氢氯吡格雷片华泰民康（沈阳）科技有限公司;苏州特瑞药业股份有限公司4CYHS2500311硫酸沙丁胺醇口服溶液辽宁海一制药有限公司3CYHS2500292硫酸特布他林雾化吸入用溶液复星医药（徐州）有限公司4CYHS2500351硫糖铝片新乡市常乐制药有限责任公司3CYHS2500284柳氮磺吡啶口服混悬液上海信谊金朱药业有限公司3CYHS2500341罗沙司他胶囊华北制药金坦生物技术股份有限公司;华北制药股份有限公司4CYHS2500303罗沙司他胶囊华北制药金坦生物技术股份有限公司;华北制药股份有限公司4CYHS2500302洛索洛芬钠贴剂前沿生物药业（南京）股份有限公司;湖南派格兰药业有限公司4CYHS2500354洛索洛芬钠贴剂前沿生物药业（南京）股份有限公司;湖南派格兰药业有限公司4CYHS2500355吗替麦考酚酯干混悬剂昆明贝克诺顿制药有限公司3CYHS2500271美索巴莫片石家庄四药有限公司3CYHS2500273蒙脱石混悬液合肥远志医药科技开发有限公司;安徽永生堂药业有限责任公司4CYHS2500320米库氯铵注射液四川美大康佳乐药业有限公司4CYHS2500332米库氯铵注射液江西远超医药科技有限公司;朗天药业（湖北）有限公司4CYHS2500340米库氯铵注射液四川美大康佳乐药业有限公司4CYHS2500333米库氯铵注射液江西远超医药科技有限公司;朗天药业（湖北）有限公司4CYHS2500339帕拉米韦氯化钠注射液湖南九维生物医药有限公司;湖南金健药业有限责任公司4CYHS2500309帕拉米韦氯化钠注射液湖南九维生物医药有限公司;湖南金健药业有限责任公司4CYHS2500308培哚普利氨氯地平片(Ⅰ)杭州和泽坤元药业有限公司;山西同达药业有限公司4CYHS2500289双醋瑞因胶囊江苏永安制药有限公司4CYHS2500345双氯芬酸二乙胺乳胶剂福建品腾药业有限公司;江苏知原药业股份有限公司4CYHS2500270碳酸氢钠注射液江西泰吉立生物医药科技有限公司;浙江赛默制药有限公司3CYHS2500295碳酸氢钠注射液江西泰吉立生物医药科技有限公司;浙江赛默制药有限公司3CYHS2500296维生素B12注射液南京赛瑞谱顿制药有限公司;山东新时代药业有限公司3CYHS2500265吸入用乙酰半胱氨酸溶液重庆莱美药业股份有限公司4CYHS2500291西格列汀二甲双胍缓释片南京易亨制药有限公司3CYHS2500350西格列汀二甲双胍缓释片华中药业股份有限公司3CYHS2500276腺苷钴胺胶囊合肥康惠医药技术有限公司;上海海虹实业（集团）巢湖今辰药业有限公司3CYHS2500313盐酸二甲双胍片石家庄四药有限公司4CYHS2500286盐酸二甲双胍片石家庄四药有限公司4CYHS2500287盐酸非索非那定干混悬剂桂林华信制药有限公司3CYHS2500300盐酸非索非那定干混悬剂桂林华信制药有限公司3CYHS2500298盐酸美金刚口服溶液常州四药制药有限公司3CYHS2500337盐酸纳美芬注射液浙江赛默制药有限公司3CYHS2500353盐酸异丙肾上腺素注射液海南倍特药业有限公司3CYHS2500305盐酸异丙肾上腺素注射液海南倍特药业有限公司3CYHS2500304叶酸片江苏贝佳制药有限公司3CYHS2500342脂肪乳氨基酸(17)葡萄糖(19%)注射液四川太平洋药业有限责任公司4CYHS2500274注射用磷丙泊酚二钠河北科源药业有限公司;仁合益康汇泽药业河北有限公司4CYHS2500285注射用磷酸特地唑胺浙江尖峰药业有限公司4CYHS2500344注射用磷酸特地唑胺珠海优润医药科技有限公司;珠海同源药业有限公司4CYHS2500314注射用硫酸艾沙康唑桂林南药股份有限公司;苏州二叶制药有限公司4CYHS2500348注射用硫酸艾沙康唑湖南赛隆药业（长沙）有限公司;湖南赛隆药业有限公司4CYHS2500335注射用培美曲塞二钠湖南赛隆药业（长沙）有限公司;山西普德药业有限公司4CYHS2500347注射用培美曲塞二钠湖南赛隆药业（长沙）有限公司;山西普德药业有限公司4CYHS2500346注射用亚胺培南西司他丁钠珠海优润医药科技有限公司;珠海联邦制药股份有限公司4CYHS2500301注射用亚胺培南西司他丁钠珠海优润医药科技有限公司;珠海联邦制药股份有限公司4CYHS2500299唑来膦酸注射液四川太平洋药业有限责任公司3CYHS2500323ω-3鱼油中/长链脂肪乳注射液贝朗医疗（苏州）有限公司4CYHS2500356ω-3鱼油中/长链脂肪乳注射液贝朗医疗（苏州）有限公司4CYHS2500357 4、新增一致性评价补充申报药品名称企业名称受理号醋酸甲羟孕酮片浙江仙琚制药股份有限公司CYHB2550051醋酸甲羟孕酮片浙江仙琚制药股份有限公司CYHB2550050丁溴东莨菪碱注射液中孚药业股份有限公司CYHB2550053瑞巴派特片浙江大冢制药有限公司CYHB2550052盐酸甲氧氯普胺注射液成都倍特药业股份有限公司CYHB2550049注射用头孢他啶深圳信立泰药业股份有限公司CYHB2550048注射用头孢他啶深圳信立泰药业股份有限公司CYHB2550047 数据来源：摩熵医药

一致性评价上市批准专利到期

2025-01-19

·信狐药迅

恒瑞PCSK9抑制剂自研降脂新药瑞卡西单抗、石药降糖药普卢格列汀获批上市| 新获批(1.13-1.19）

每周药品注册获批数据，分门别类呈现，一目了然。(1.13-1.19）新药上市申请药品名称企业注册分类受理号普卢格列汀片石药集团欧意药业有限公司1CXHS2300048赛沃替尼片和记黄埔医药(上海)有限公司2.4CXHS2400022赛沃替尼片和记黄埔医药(上海)有限公司2.4CXHS2400021注射用瑞卡西单抗广东恒瑞医药有限公司1CXSS2300046 新药临床申请药品名称企业注册分类受理号SYHA1813口服溶液上海润石医药科技有限公司1CXHL2401166SYHA1813口服溶液上海润石医药科技有限公司1CXHL2401165SYHA1813口服溶液上海润石医药科技有限公司1CXHL2401164CVI-2742胶囊西威埃医药技术(上海)有限公司1CXHL2401191CVI-2742胶囊西威埃医药技术(上海)有限公司1CXHL2401190DF-003胶囊上海药苑生物科技有限公司1CXHL2401186DF-003胶囊上海药苑生物科技有限公司1CXHL2401185DF-003胶囊上海药苑生物科技有限公司1CXHL2401184QLS1304片齐鲁制药有限公司1CXHL2401194QLS1304片齐鲁制药有限公司1CXHL2401195QLS1304片齐鲁制药有限公司1CXHL2401196ASN-3186胶囊上海亚虹医药科技有限公司1CXHL2401204NSP-1047A片诺沃斯达药业(上海)有限公司1CXHL2401210NSP-1047A片诺沃斯达药业(上海)有限公司1CXHL2401209GH56胶囊勤浩医药(苏州)有限公司1CXHL2401208GH56胶囊勤浩医药(苏州)有限公司1CXHL2401207GH56胶囊勤浩医药(苏州)有限公司1CXHL2401206ASN-3186胶囊上海亚虹医药科技有限公司1CXHL2401205Sonrotoclax薄膜包衣片百济神州(苏州)生物科技有限公司1CXHL2401221Sonrotoclax薄膜包衣片百济神州(苏州)生物科技有限公司1CXHL2401220Sonrotoclax薄膜包衣片百济神州(苏州)生物科技有限公司1CXHL2401219达希替尼片轩竹生物科技股份有限公司1CXHL2401216达希替尼片轩竹生物科技股份有限公司1CXHL2401215Sonrotoclax薄膜包衣片百济神州(苏州)生物科技有限公司1CXHL2401222PLB1004胶囊鞍石药业(宁波)有限责任公司1CXHL2401226PLB1004胶囊鞍石药业(宁波)有限责任公司1CXHL2401225ANS014004片北京鞍石生物科技股份有限公司1CXHL2401224ANS014004片北京鞍石生物科技股份有限公司1CXHL2401223AZD0022阿斯利康全球研发(中国)有限公司1CXHL2401229AZD0022阿斯利康全球研发(中国)有限公司1CXHL2401228ICP-248片北京诺诚健华医药科技有限公司1CXHL2401217盐酸(R)-氯胺酮注射液江苏豪森药业集团有限公司2.1;2.4CXHL2401161盐酸(R)-氯胺酮注射液江苏豪森药业集团有限公司2.1;2.4CXHL2401159HQ2216注射液百诚医药(珠海横琴)有限公司2.2CXHL2401154注射用艾博韦泰前沿生物药业(南京)股份有限公司2.4CXHL2401176甲磺酸伏美替尼片上海艾力斯医药科技股份有限公司2.4CXHL2401238RGL-2201注射液上海瑞宏迪医药有限公司1CXSL2400756GenSci120注射液长春金赛药业有限责任公司1CXSL2400763GenSci120注射液长春金赛药业有限责任公司1CXSL2400765IBI3014信达生物制药(苏州)有限公司1CXSL2400768注射用KY-0301科弈(浙江)药业科技有限公司1CXSL2400767 仿制药申请药品名称企业注册分类受理号羧甲司坦口服溶液海南斯达制药有限公司3CYHS2300946奥美拉唑碳酸氢钠干混悬剂湖北邦泽医药有限公司3CYHS2301623氨氯地平贝那普利胶囊河北龙海药业有限公司3CYHS2301852二羟丙茶碱注射液河北千康医药科技有限责任公司3CYHS2302021帕拉米韦注射液长春澜江医药科技有限公司3CYHS2302932盐酸右哌甲酯缓释胶囊河南中帅药业有限公司3CYHS2303628普瑞巴林口服溶液常州四药制药有限公司3CYHS2301334氨溴特罗口服溶液南京创迪生物技术有限公司3CYHS2302950吡拉西坦注射液西安达莫制药有限公司3CYHS2400403磷酸奥司他韦胶囊植恩生物技术股份有限公司4CYHS2400901磷酸奥司他韦胶囊福建省闽东力捷迅药业股份有限公司4CYHS2400923托吡酯片海南日中天制药有限公司4CYHS2301074注射用两性霉素B脂质体江西艾施特制药有限公司4CYHS2301518注射用替考拉宁重庆药友制药有限责任公司4CYHS2301539复方甘草酸苷片东阳祥昇医药科技有限公司4CYHS2301720甲磺酸仑伐替尼胶囊吉林敖东洮南药业股份有限公司4CYHS2301719甲磺酸仑伐替尼胶囊吉林敖东洮南药业股份有限公司4CYHS2301718地诺孕素片南通联亚药业股份有限公司4CYHS2301847硫酸特布他林雾化吸入用溶液浙江金华康恩贝生物制药有限公司4CYHS2301885钆喷酸葡胺注射液四川国瑞药业有限责任公司4CYHS2301898间苯三酚注射液江苏悦兴药业有限公司4CYHS2302047非那雄胺片乐泰药业有限公司4CYHS2302057非那雄胺片乐泰药业有限公司4CYHS2302056西格列汀二甲双胍片(II)江苏康缘药业股份有限公司4CYHS2302127乳果糖口服溶液安徽美来药业股份有限公司4CYHS2302196吸入用异丙托溴铵溶液浙江金华康恩贝生物制药有限公司4CYHS2302237盐酸莫西沙星片河北天成药业股份有限公司4CYHS2302521复方氨基酸注射液(18AA-IX)四川科伦药业股份有限公司4CYHS2302546马来酸阿伐曲泊帕片瑞阳制药股份有限公司4CYHS2302556盐酸氮斯汀滴眼液浙江视方极医药科技有限公司4CYHS2302677甲苯磺酸艾多沙班片齐鲁制药有限公司4CYHS2302693甲苯磺酸艾多沙班片齐鲁制药有限公司4CYHS2302692甲苯磺酸艾多沙班片齐鲁制药有限公司4CYHS2302691地夸磷索钠滴眼液山东诺明康药物研究院有限公司4CYHS2302729马来酸咪达唑仑片宜昌人福药业有限责任公司4CYHS2302782氯雷他定糖浆南通广承制药有限公司4CYHS2302830伊布替尼胶囊江西科睿药业有限公司4CYHS2302871玛巴洛沙韦片郑州泰丰制药有限公司4CYHS2302877马来酸阿伐曲泊帕片湖南明瑞制药股份有限公司4CYHS2302991甲钴胺注射液广州一品红制药有限公司4CYHS2303000达比加群酯胶囊浙江诺得药业有限公司4CYHS2303164达比加群酯胶囊浙江诺得药业有限公司4CYHS2303163达比加群酯胶囊浙江诺得药业有限公司4CYHS2303162苯磺酸氨氯地平片广州一品红制药有限公司4CYHS2303193苯磺酸氨氯地平片广州一品红制药有限公司4CYHS2303192盐酸氮斯汀滴眼液浙江视方极医药科技有限公司4CYHS2303213沙库巴曲缬沙坦钠片江苏德源药业股份有限公司4CYHS2303296注射用紫杉醇(白蛋白结合型)河北天成药业股份有限公司4CYHS2303294硫酸羟氯喹片福建广生堂药业股份有限公司4CYHS2303516酒石酸溴莫尼定滴眼液广东众生药业股份有限公司4CYHS2303512贝前列素钠片江西科睿药业有限公司4CYHS2303507尼可地尔片浙江赛默制药有限公司4CYHS2303503罗沙司他胶囊哈尔滨三联药业股份有限公司4CYHS2302026罗沙司他胶囊哈尔滨三联药业股份有限公司4CYHS2302025罗沙司他胶囊广州康臣药业有限公司4CYHS2302564罗沙司他胶囊北京福元医药股份有限公司4CYHS2302942罗沙司他胶囊北京福元医药股份有限公司4CYHS2302941富马酸福莫特罗吸入溶液长风药业股份有限公司4CYHS2302621富马酸福莫特罗吸入溶液南京力成药业有限公司4CYHS2303034盐酸伊托必利片裕松源药业有限公司4CYHS2404103氯沙坦钾氢氯噻嗪片裕松源药业有限公司4CYHS2404128奥美沙坦酯氨氯地平片裕松源药业有限公司4CYHS2404050吸入用布地奈德混悬液浙江高跖医药科技股份有限公司4CYHS2302457玻璃酸钠滴眼液辅必成(上海)医药科技有限公司4CYHS2400844艾考糊精腹膜透析液芜湖道润药业有限责任公司4CYHS2401530贝伐珠单抗注射液上海生物制品研究所有限责任公司3.3CXSS2300058重组人II型肿瘤坏死因子受体-抗体融合蛋白注射液海正生物制药有限公司3.4CXSS2300056重组人II型肿瘤坏死因子受体-抗体融合蛋白注射液海正生物制药有限公司3.4CXSS2300055德谷胰岛素利拉鲁肽注射液正大天晴药业集团股份有限公司3.3CXSL2400772 进口申请药品名称企业注册分类受理号厄达替尼片Janssen Biotech, Inc.5.1JXHS2300124厄达替尼片Janssen Biotech, Inc.5.1JXHS2300123厄达替尼片Janssen Biotech, Inc.5.1JXHS2300125帕博利珠单抗注射液Merck Sharp & Dohme LLC3.1JXSS2400034艾沙妥昔单抗注射液Sanofi Winthrop Industrie3.1JXSS2300090艾沙妥昔单抗注射液Sanofi Winthrop Industrie3.1JXSS2300091奥拉帕利片Natco Pharma Limited5.2JYHS2300075奥拉帕利片Natco Pharma Limited5.2JYHS2300074MRG-001注射液MEDREGEN, LLC2.3;2.4JXHL2400259Vorasidenib片Institut de Recherches Internationales Servier2.4JXHL2400265Vorasidenib片Institut de Recherches Internationales Servier2.4JXHL240026613价肺炎球菌多糖结合疫苗Pfizer Europe MA EEIG3.1JXSL2400209Itepekimab注射液Sanofi-Aventis Recherche & Developpement1JXSL2400200注射用德曲妥珠单抗Daiichi Sankyo, Inc.2.2JXSL2400217 中药相关申请药品名称企业注册分类受理号苦丁茶总皂苷提取物华医神农(珠海)医药科技有限公司1.2CXZL2400069苦丁茶皂苷片华医神农(珠海)医药科技有限公司1.2CXZL2400068 注：橙色字体部分结论为不批准或收到通知件；

申请上市上市批准临床申请

100 项与伊布替尼相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10223	伊布替尼	L01XE27	DB09053

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
淋巴浆细胞性淋巴瘤	日本	Janssen Pharmaceutical KK	2022-12-23
移植物抗宿主病	日本	Janssen Pharmaceutical KK	2021-09-27
边缘区B细胞淋巴瘤	美国	Pharmacyclics LLC	2017-01-18
慢性移植物抗宿主病	墨西哥	Janssen-Cilag SA de CV	2015-03-01
小淋巴细胞淋巴瘤	墨西哥	Janssen-Cilag SA de CV	2015-03-01
复发性套细胞淋巴瘤	欧盟	Janssen-Cilag International NV	2014-10-21
复发性套细胞淋巴瘤	挪威	Janssen-Cilag International NV	2014-10-21
复发性套细胞淋巴瘤	列支敦士登	Janssen-Cilag International NV	2014-10-21
复发性套细胞淋巴瘤	冰岛	Janssen-Cilag International NV	2014-10-21
难治性套细胞淋巴瘤	挪威	Janssen-Cilag International NV	2014-10-21
难治性套细胞淋巴瘤	列支敦士登	Janssen-Cilag International NV	2014-10-21
难治性套细胞淋巴瘤	冰岛	Janssen-Cilag International NV	2014-10-21
难治性套细胞淋巴瘤	欧盟	Janssen-Cilag International NV	2014-10-21
巨球蛋白血症	韩国	Janssen Korea Ltd.	2014-08-08
慢性淋巴细胞白血病	美国	Pharmacyclics LLC	2014-02-12
套细胞淋巴瘤	美国	Pharmacyclics LLC	2013-11-13

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
小淋巴细胞淋巴瘤	临床3期	意大利	Pharmacyclics LLC	2012-06-01
小淋巴细胞淋巴瘤	临床3期	比利时	Janssen Research & Development LLC	2012-06-01
小淋巴细胞淋巴瘤	临床3期	爱尔兰	Janssen Research & Development LLC	2012-06-01
小淋巴细胞淋巴瘤	临床3期	波兰	Pharmacyclics LLC	2012-06-01
小淋巴细胞淋巴瘤	临床3期	波兰	Janssen Research & Development LLC	2012-06-01
小淋巴细胞淋巴瘤	临床3期	法国	Janssen Research & Development LLC	2012-06-01
小淋巴细胞淋巴瘤	临床3期	美国	Janssen Research & Development LLC	2012-06-01
小淋巴细胞淋巴瘤	临床3期	英国	Pharmacyclics LLC	2012-06-01
小淋巴细胞淋巴瘤	临床3期	西班牙	Pharmacyclics LLC	2012-06-01
小淋巴细胞淋巴瘤	临床3期	法国	Pharmacyclics LLC	2012-06-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03149315 (CTgov)	临床2期	食物过敏 \| 过敏	6	Ibrutinib (Ibrutinib)	鏇構鬱壓獵廠鬱醖窪淵(選壓簾選網築淵餘製膚) = 網糧選壓蓋衊鏇願願夢繭獵齋醖夢襯願膚膚窪 (壓齋選願膚顧鹽襯繭製, 觸構衊膚範鏇憲膚餘廠 ~ 淵鏇選簾顧願鏇鏇獵網) 更多	-	2025-01-17
				Ibrutininb (Ibrutininb)	選齋餘餘範構憲選網艱(齋窪積鏇蓋衊觸積憲觸) = 鏇繭窪糧齋衊壓網壓襯鏇觸獵壓餘鬱壓遞觸淵 (憲築製鬱艱窪艱築觸淵, 製願糧憲衊糧憲簾壓遞 ~ 壓遞觸夢壓廠艱簾憲膚)
NCT04477486 (CTgov)	临床2期	套细胞淋巴瘤	13	Ibrutinib+Venetoclax	觸製淵襯簾築艱觸鑰憲(鏇簾淵選鏇鹽蓋窪醖構) = 蓋衊窪衊製膚艱鑰鹽醖製膚艱壓夢淵築鑰衊廠 (鏇衊鹹鬱鬱鹹廠鹹網鏇, 淵壓餘鏇廠選鹽夢襯齋 ~ 蓋鬱築糧廠簾網鹽膚網)	-	2025-01-14
NCT05564052 (VEGA, CTgov)	临床2期	套细胞淋巴瘤	36	Ibrutinib+Rituximab (Arm A1: Ibrutinib 560 mg + Rituximab 375 mg/m^2)	獵夢廠齋觸膚餘鏇艱齋(鹽淵觸鬱積網餘鏇簾夢) = 襯鑰齋顧鏇廠簾齋構鹹膚積簾廠廠鹽鬱夢襯膚 (齋築獵鬱窪顧簾簾蓋壓, 醖糧醖鏇鹽繭構衊獵餘 ~ 窪獵鑰淵鹽願鑰醖願餘) 更多	-	2025-01-13
				Ibrutinib+Rituximab (Arm A2: Ibrutinib 420 mg + Rituximab 375 mg/m^2)	獵夢廠齋觸膚餘鏇艱齋(鹽淵觸鬱積網餘鏇簾夢) = 淵壓齋醖積選製獵願簾膚積簾廠廠鹽鬱夢襯膚 (齋築獵鬱窪顧簾簾蓋壓, 構醖齋遞積衊築淵壓築 ~ 鬱壓願艱築鏇鏇觸顧壓) 更多
NCT02643667 (CTgov)	临床2期	局限性前列腺癌	27	Radical prostatectomy+Ibrutinib (Phase I: Ibrutinib)	醖範構壓廠鹹網鑰餘製(網壓鏇壓廠鹹顧壓蓋艱) = 積觸餘艱蓋顧衊艱鑰繭糧簾襯憲衊繭糧壓廠繭 (顧顧衊醖獵積顧選選觸, 遞窪窪網糧鏇淵獵憲襯 ~ 觸夢遞繭獵繭繭積鹹廠) 更多	-	2025-01-08
				Radical prostatectomy+Ibrutinib (Safety Run-In and Phase II: Ibrutinib)	醖範構壓廠鹹網鑰餘製(網壓鏇壓廠鹹顧壓蓋艱) = 觸遞觸廠衊獵簾構醖鑰糧簾襯憲衊繭糧壓廠繭 (顧顧衊醖獵積顧選選觸, 餘觸窪遞壓衊糧簾鹹艱 ~ 夢鬱鏇膚鬱鬱鬱鹽範選) 更多
NCT02207062 (CTgov)	临床2期	复发性非霍奇金淋巴瘤 \| 难治性转化惰性 B 细胞非霍奇金淋巴瘤	20	Laboratory Biomarker Analysis+Ibrutinib	(憲糧選艱夢鹽構夢衊壓) = 鏇鏇製醖壓憲壓淵選簾範鹹願網醖鹽憲鏇齋憲 (構襯醖製鏇獵鹽廠簾願, 築淵廠網憲醖糧壓願積 ~ 淵鏇齋築襯糧膚鹽積壓) 更多	-	2025-01-07
NCT03734016 (ALPINE, Pubmed \| Blood)	临床3期	慢性淋巴细胞白血病 del(17p) \| TP53 mutation	652	Zanubrutinib	繭選選蓋觸鹽壓鹹膚製(鏇夢蓋淵遞遞鏇衊憲範) = no cardiac deaths were reported with zanubrutinib vs 6 cardiac deaths with ibrutinib 鹹艱廠廠廠蓋積窪築膚 (築鹽襯淵襯選選製鹽範 ) 更多	积极	2024-12-26
				Ibrutinib
NCT04235036 (CTgov)	临床2期	慢性移植物抗宿主病	15	Ibrutinib+Rituximab	觸淵廠選範夢鬱襯齋鏇(獵鏇襯鑰衊製網顧艱艱) = 築糧顧膚衊網積艱鹽網醖衊鏇夢獵構遞範觸繭 (鹹鏇遞艱夢糧壓網襯蓋, 壓製襯構鑰壓鬱鹹窪醖 ~ 觸窪遞鹽醖顧鏇鑰鬱獵) 更多	-	2024-12-13
ASH2024 人工标引	临床1/2期	套细胞淋巴瘤	36	Venetoclax 2IbrutinibPrednisoneObinutuzumabLenalidomide	(壓觸觸齋鹹鑰鑰遞繭鑰) = thrombocytopenia (14%), neutropenia (13%), and anemia (10%) 蓋網簾壓齋廠顧夢範壓 (積蓋淵醖衊範鏇觸窪糧 ) 更多	积极	2024-12-09
				Venetoclax 4IbrutinibPrednisoneObinutuzumabLenalidomide
NCT03620903 (ECWM-2, ASH2024) 人工标引	临床2期	巨球蛋白血症一线	53	Bortezomib+Ibrutinib+Rituximab	(鬱鹹獵壓窪鑰願構齋鹽) = 夢齋選構範鏇艱蓋網餘顧醖餘構選顧鹹範糧範 (繭範憲糧鏇夢齋積蓋糧 ) 更多	积极	2024-12-09
ASH2024	N/A	-	-	Ibrutinib + rituximab	(獵構艱觸廠積鬱窪膚艱) = 築糧窪窪選餘築餘製顧淵壓膚鏇構壓獵製廠淵 (餘齋顧獵齋鹹廠積窪範, 76.8 ~ 84.9) 更多	-	2024-12-09